tiprankstipranks
Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers
The Fly

Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers

Leerink analyst David Risinger notes AbbVie (ABBV) announced on November 11 that emraclidine’s pivotal Phase 2 trials, EMPOWER-1 and EMPOWER-2, did not meet their primary endpoints. The firm argues that this outcome is a clear positive positive for Bristol Myers (BMY) because its recently approved schizophrenia treatment Cobenfy will not face competition from emraclidine. Leerink has a Market Perform rating on AbbVie’s shares.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App